Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Nov 24;2(12):1065–1075. doi: 10.1158/1940-6207.CAPR-09-0010

Fig. 5. Ssat and Clusterin are upregulated in TRAMP and WT prostates following 0.3% GTP treatment.

Fig. 5

A) Ssat mRNA expression in prostates from either control or GTP-treated TRAMP mice at 12 and 24 weeks of age was measured by qRT-PCR as described in Materials and Methods. B) Ssat mRNA expression in prostates from control or GTP-treated WT mice at 12 and 24 weeks of age was measured by qRT-PCR as described in Materials and Methods. C) Clusterin mRNA expression in prostates from control or GTP-treated TRAMP mice at 12 and 24 weeks of age was measured by qRT-PCR as described in Materials and Methods. D) Clusterin mRNA expression in prostates from control or GTP-treated WT mice at 12 and 24 weeks of age was measured by qRT-PCR as described in Materials and Methods. Mice were administered GTPs beginning at 4 weeks of age. Each symbol represents an individual sample and the bar indicates the median of each group. Mann-Whitney Test was used to determine significant differences.